Respiratory News and Research

RSS

Study: Risk factors in indoor environment of modern apartments related to pneumonia among children

Childhood pneumonia is the leading causes of death among children in China and worldwide. Using coal or wood as cooking fuel in rural area was considered as major cause of Pneumonia. However, the incidence of childhood pneumonia is still high in urban modern cities.

24 Jun 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, an RNAi therapeutic targeting complement component C5.

21 Jun 2013

HIV-derived antibacterial compounds could be potential treatments for drug-resistant bacterial infections

A team of researchers at the University of Pittsburgh has developed antibacterial compounds, derived from the outer coating of HIV, that could be potential treatments for drug-resistant bacterial infections and appear to avoid generating resistance. These new agents are quite small, making them inexpensive and easy to manufacture.

20 Jun 2013

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

20 Jun 2013

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

20 Jun 2013

NO2 exposure in infancy is strongly linked with later development of childhood asthma

A research team led by UCSF scientists has found that exposure in infancy to nitrogen dioxide (NO2), a component of motor vehicle air pollution, is strongly linked with later development of childhood asthma among African Americans and Latinos.

19 Jun 2013

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013

Montana scientist receives ICAAC Young Investigator Award for research on memory responses to infection

Joshua Obar, Ph.D., Department of Immunology and Infectious Diseases, Montana State University-Bozeman, has been honored with a 2013 ICAAC Young Investigator Award for his research on factors affecting the regulation of immunological memory responses to infection.

19 Jun 2013

MRI screening of aortic atherosclerosis can predict risk of heart attacks and other CVDs

Magnetic resonance imaging (MRI) of aortic atherosclerosis can predict the risk of heart attacks and other cardiovascular events in otherwise healthy individuals, researchers at UT Southwestern Medical Center have found.

19 Jun 2013

Sorin Group announces CE mark approval, launch of REPLY 200 family of pacemakers with SAM

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today CE mark approval and the European commercial launch of the REPLY 200 family of pacemakers featuring Sleep Apnea Monitoring.

18 Jun 2013

Multidisciplinary health care approach can cut the rate of common airway infection among children

An initiative that combines a multidisciplinary health care approach with a range of preventive measures could cut the rate of a common airway infection among children in intensive care by more than half, a new study suggests.

18 Jun 2013

International researchers solve three-dimensional structure of respiratory syncytial virus

Young children and the elderly are especially susceptible to respiratory syncytial virus. The three-dimensional structure of respiratory syncytial virus has been solved by an international team from Finland and Switzerland.

18 Jun 2013

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.

17 Jun 2013

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Pharmacyclics, Inc. today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma or diffuse large B-cell lymphoma.

17 Jun 2013

Bristol-Myers Squibb, AstraZeneca release statement on ADA's efforts toward incretin-based therapies

Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.

17 Jun 2013

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

InterMune, Inc. today announced that the Board of the Italian Drug Agency has approved the pricing and reimbursement conditions for Esbriet (pirfenidone), and that the agreement has been published in the Official Gazette, the official journal of the government of Italy.

15 Jun 2013

Educating pediatricians on appropriate antibiotic usage can improve outcomes in children’s infections

As disease-causing microbes continue their worrisome trend of developing resistance to commonly used antibiotics, public health experts have called for more selective use of those medicines. A new study suggests that educating pediatricians in their offices, and auditing their prescription patterns, encourages them to choose more appropriate antibiotics for children with common respiratory infections.

14 Jun 2013

Respiratory News and Research

Study: Risk factors in indoor environment of modern apartments related to pneumonia among children

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

HIV-derived antibacterial compounds could be potential treatments for drug-resistant bacterial infections

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

NO2 exposure in infancy is strongly linked with later development of childhood asthma

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Montana scientist receives ICAAC Young Investigator Award for research on memory responses to infection

MRI screening of aortic atherosclerosis can predict risk of heart attacks and other CVDs

Sorin Group announces CE mark approval, launch of REPLY 200 family of pacemakers with SAM

Multidisciplinary health care approach can cut the rate of common airway infection among children

International researchers solve three-dimensional structure of respiratory syncytial virus

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

European Commission amends marketing authorisation for Celgene's REVLIMID

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Bristol-Myers Squibb, AstraZeneca release statement on ADA's efforts toward incretin-based therapies

Teva to present abstracts on AZILECT at MDS meeting

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

Educating pediatricians on appropriate antibiotic usage can improve outcomes in children’s infections

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News